Scribd Logo
Upload

Welcome to Scribd!

  • 127 views

    Impetigo

    Uploaded by

    kikimasyhur
    1) Impetigo is a common bacterial skin infection caused by Staphylococcus aureus or Streptococcus pyogenes that presents as either bullous or non-bullous lesions. 2) Non-bullous impetigo is the most common type, appearing as fluid-filled blisters that rupture and leave yellow crusts. Bullous impetigo features large fragile blisters caused by S. aureus toxins. 3) Diagnosis is usually clinical but cultures may help identify pathogens. Topical or oral antibiotics are first-line treatments, with topical mupirocin, retapamulin

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd

    Impetigo

    Uploaded by

    kikimasyhur
    127 views16 pages
    1) Impetigo is a common bacterial skin infection caused by Staphylococcus aureus or Streptococcus pyogenes that presents as either bullous or non-bullous lesions. 2) Non-bullous impetigo is the most common type, appearing as fluid-filled blisters that rupture and leave yellow crusts. Bullous impetigo features large fragile blisters caused by S. aureus toxins. 3) Diagnosis is usually clinical but cultures may help identify pathogens. Topical or oral antibiotics are first-line treatments, with topical mupirocin, retapamulin

    Original Description:

    ppt jurding impetigo

    Copyright

    © © All Rights Reserved

    Available Formats

    PPTX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    1) Impetigo is a common bacterial skin infection caused by Staphylococcus aureus or Streptococcus pyogenes that presents as either bullous or non-bullous lesions. 2) Non-bullous impetigo is the most common type, appearing as fluid-filled blisters that rupture and leave yellow crusts. Bullous impetigo features large fragile blisters caused by S. aureus toxins. 3) Diagnosis is usually clinical but cultures may help identify pathogens. Topical or oral antibiotics are first-line treatments, with topical mupirocin, retapamulin

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd
    Download as pptx, pdf, or txt
    127 views16 pages

    Impetigo

    Uploaded by

    kikimasyhur
    1) Impetigo is a common bacterial skin infection caused by Staphylococcus aureus or Streptococcus pyogenes that presents as either bullous or non-bullous lesions. 2) Non-bullous impetigo is the most common type, appearing as fluid-filled blisters that rupture and leave yellow crusts. Bullous impetigo features large fragile blisters caused by S. aureus toxins. 3) Diagnosis is usually clinical but cultures may help identify pathogens. Topical or oral antibiotics are first-line treatments, with topical mupirocin, retapamulin

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd
    Download as pptx, pdf, or txt
    of 16

    Journal Reading

    IMPETIGO: DIAGNOSIS AND TREATMENT


    Ahmad Rizky
    1102013014

    Dosen Pembimbing : dr. Umi Rinasari, MARS, Sp.KK

    Kepaniteraan Klinik Ilmu Kulit dan Kelamin


    Fakultas Kedokteran Universitas Yarsi
    Rumah Sakit Bhayangkara Tk.I R. Said Sukanto
    Periode 19 November – 22 Desember 2018
    Definition

    ■ Impetigo is a common bacterial skin infection caused by


    Staphylococcus aureus, group A beta-hemolytic Streptococcus
    pyogenes, a combination of the two, or less commonly, anaerobic
    bacteria
    Clinical Presentation

    ■ There are two presentations of impetigo:


    ■ Bullous
    ■ Non-Bullous (also known as impetigo
    contagiosa)
    NONBULLOUS IMPETIGO

    ■ Nonbullous impetigo is the most common presentation, comprising 70% of cases


    ■ can be further classified as primary or the more prevalent secondary (common)
    form.
    BULLOUS IMPETIGO
    ■ caused only by S. aureus and is characterized by large,
    fragile, flaccid bullae that can rupture and ooze yellow
    fluid (Fig.2)
    ■ The pathognomonic collarette of scales on its periphery
    develops after the bullae rupture, leaving a thin, brown
    crust on the remaining erosions (Fig.3)
    ■ The larger bullae form because of exfoliative toxins produced by S.
    aureus strains that cause loss of cell adhesion in the superficial
    epidermis
    ■ typically found on the trunk, axilla, and extremities, and in
    intertriginous (diaper) areas.
    DIAGNOSIS

    ■ The diagnosis of nonbullous and bullous impetigo is nearly always


    clinical.
    ■ In patients in whom first-line therapy fails, culture of the pus or
    bullous fluid, not the intact skin, may be helpful for pathogen
    identification and anti- microbial susceptibilities
    COMPLICATIONS

    ■ Usually a self-limited condition


    ■ Although it’s rare, still complications can occur
    ■ Complications include Ecthyma, septicemia, osteomyelitis, septic
    arthritis, etc.
    TREATMENT

    ■ Treatment options include topical and systemic antibiotics and topical disinfectants.

    ■ TOPICAL ANTIBIOTICS
    – have the advantage of being applied only where needed, minimizing antibiotic
    resistance and avoiding systemic adverse effects

    – Three topical antibiotic preparations recommended for impetigo are mupirocin


    2% cream or ointment, retapamulin 1% ointment, and fusidic acid
    ORAL ANTIBIOTICS

    ■ Can be used for impetigo with large bullae or when topical therapy is
    impractical
    ■ Treatment for 7 days is usually sufficient, but can be extended
    accordingly
    TOPICAL DISINFECTANTS

    ■ There are some studies on the benefits of nonantibiotic treatments,


    such as disinfectant soaps, but they lack statistical power.

    ■ Appears to be less effective than topical antibiotics


    NATURAL THERAPIES

    ■ evidence is insufficient to recommend or dismiss popular herbal


    treatments for impetigo
    ■ Some natural remedies such as Tea tree, Manuka honey, etc, have
    been anecdotally successful
    FUTURE TREATMENTS

    ■ Future treatments for impetigo might include minocycline foam


    (Foamix), which has successfully completed phase II trials, and
    Ozenoxacin, a topical quinolone that has successfully completed
    phase III clinical tri- als
    THANK YOU

    You might also like